Mylan closes deal on Cold-Eeze acquisition

PITTSBURGH — Mylan on Wednesday announced the successful acquisition of the global rights to the Cold-Eeze brand cold remedy line from ProPhase Labs.



"The completion of this transaction is an important step as we continue to expand our consumer healthcare offerings," stated Heather Bresch, CEO Mylan. "Cold-Eeze is now Mylan's largest U.S. consumer healthcare brand and is part of a growing portfolio of over-the-counter products in the U.S."



The transaction provides Mylan all assets and rights relating to the Cold-Eeze brand, including all U.S. businesses and U.S. and international trademarks. The Cold-Eeze family of brands includes leading over-the-counter cold remedies sold as lozenges, gummies, oral sprays, caplets, QuickMelts and oral liquid dose forms in the U.S.